Form 4: Intra-Cellular Therapies EVP, Chief Medical Officer Suresh K. Durgam Reports Stock Sales

Suresh K. Durgam, EVP and Chief Medical Officer of Intra-Cellular Therapies, Inc., reports multiple sales of common stock between March 7 and March 11, 2024, under a pre-arranged Rule 10b5-1 trading plan.

Summary

• Suresh K. Durgam, the EVP and Chief Medical Officer of Intra-Cellular Therapies, Inc. (ITCI), filed a Form 4 detailing changes in beneficial ownership.
• The report covers transactions from March 7, 2024, to March 11, 2024.
• Durgam sold shares of common stock under a Rule 10b5-1 trading plan adopted on March 13, 2023.
• On March 7, 2024, he sold 3,728 shares at $66.34 and 2,722 shares at $66.86.
• On March 10, 2024, 7,345 restricted stock units vested and converted into common stock.
• On March 11, 2024, he sold 2,179 shares at $65.06, 872 shares at $65.89, and 661 shares at $66.96.
• The sales were executed at varying prices within specified ranges, with Durgam committing to provide detailed price information upon request.
• A majority of the proceeds from the sales will be used to cover the reporting person's tax liability arising from the vesting of restricted stock units.

Sentiment

Score: 5

Explanation: The sentiment is neutral. The stock sales are part of a pre-planned trading strategy to cover tax liabilities, which is a common practice. There is no indication of any negative outlook or concerns about the company's performance.

Positives

• The sales were conducted under a pre-arranged Rule 10b5-1 trading plan, suggesting they were planned in advance and not based on immediate market sentiment.

Negatives

• The sales by a high-ranking executive could be interpreted negatively by some investors, although the stated reason is to cover tax liabilities.

Risks

• Executive stock sales can sometimes create short-term downward pressure on the stock price.

Industry Context

Executive stock sales are a common occurrence in publicly traded companies. They are often related to compensation and tax planning. The use of a 10b5-1 plan is a standard practice to avoid insider trading concerns.

Comparison to Industry Standards

• Executive compensation packages often include stock options and restricted stock units, which vest over time.
• Sales of stock by executives are generally viewed in the context of their overall holdings and the company's performance.
• Rule 10b5-1 plans are a common tool used by executives to manage their stock sales in a compliant manner.

Stakeholder Impact

• The stock sales could have a minor short-term impact on shareholders due to potential downward pressure on the stock price.

Key Dates